The recently introduced drug class of neprilysin inhibitors to patients suffering from heart failure raised the question whether ANP is the better alternative compared to BNP to adequately reflect effects during therapy with sacubitril/valsartan (Entresto®) (5). This evidence concerns the gene NPPB and heart failure.